

<b>Note: Unless otherwise specified, blank values indicate missing data. In addition, due to data cleaning efforts, data may contain slight discrepancies from that reported in Table 1, Table 3 and Figure 1 in the publication.</b>			
<b>Data items</b>	<b>Variable Name</b>	<b>Coding/Description</b>	<b>Note</b>
Patient identifier	uid		De-identified patient ID, not ECOG case ID
Whether the case was included in the primary analysis	indicator	0=no, 1=yes	
Eligibility	eligibility	1=no, 2=yes	
GM-CSF	gmcsf	0=no, 1=yes	
Peptide vaccine	peptide	0=no, 1=yes	Only patients on arms A, B, C, and D received either peptide vaccine or peptide vaccine placebo, and had value of 1 or 0 for this variable
Treatment arm	trtarm	A: GM-CSF + Peptide Vaccination B: GM-CSF Placebo + Peptide Vaccination C: GM-CSF + Peptide Placebo D: GM-CSF Placebo + Peptide Placebo E: GM-CSF F: GM-CSF Placebo	
Disease recurrence	recur	0=no, 1=yes	
RFS status	rfs_s	0=censor, 1=RFS event	As of database on 10/08/2012
RFS time in months	rfs_m	Continuous variable	As of database on 10/08/2012
OS status	surv_s	0=censor, 1=died	As of database on 10/08/2012
OS time in months	surv_m	Continuous variable	As of database on 10/08/2012
Stratification factor -HLA-A2 status	var1	1=positive, 2=negative	
Stratification factor -site of metastases	var2	1=visceral,	

		2=non-visceral, 3=visceral and non-visceral, 4=no metastases	
Stratification factor -number of metastatic lesions	var3	1=1, 2=2-3, 3=4 or more, 4=0	
Age at study entry (years)	age	Continuous variable	
Sex	gender	0=male 1=female	
Race	race	1=White, 2=Other, 3=Pre-NCI	
ECOG performance status	ecogps	0=0, 1=1	
t-primary tumor	breslow	1=Breslow<=.75mm, 2= Breslow .76-1.50 mm, 3= Breslow 1.51 -4.0 mm, 4=Breslow>=4.1 mm or satellite(s) within 2cm	
n-nodal involvement at primary presentation	node	0=no regional lymph node involvement, 1=one regional node station, node(s) mobile and diameter<=3cm, 2=lymph node station, diameter>3cm, or fixed, 3=multiple regional modal groups	
m- metastatic involvement at primary presentation	mets	0=no distant metastases, 1=skin or subcutaneous lesions beyond site of primary and its drainage, 2=visceral metastases	
Depth of invasion (Clark level) of primary tumor	clark	1=Clark level I 2=Clark level II 3=Clark level III 4=Clark level IV 5=Clark level V	
Disease stage at study entry	stage	1=stage IIIA 2=stage IIIB 3=stage IIIC 4=stage M1a 5=stage M1b 6=stage M1c	

Primary tumor site	primarysite	1=head and neck, 2=upper limb, 3=lower limb, 4=subungual, 5=trunk, 6=anogenital, 7=ocular, 8=mucosal, 9=other	
No. of positive nodes at primary presentation	pnode	0=0 node, 1=1-3 nodes, 2= >=4 nodes	
Pigmentation-histology of primary	pigmentation	1=Amelanotic, 2=Melanotic	
Ulceration-histology of primary	ulcer	1=no, 2=yes	
Lymphoid infiltration of primary tumor	lympinfil	1=Absent, 2=Sparse focal infiltrate, 3=Dense or prominent	
Current evidence disease	ref05	1=no, 2=yes	
Matted lymph nodes	mat_lymph	1=no, 2=yes	
Previous immunotherapy	immuno	1=no, 2=yes	
Previous chemotherapy	chemo	1=no, 2=yes	
Previous radiation therapy	radrx	1=no, 2=yes	
Surgical treatment: initial biopsy of primary	ref18	1=no, 2=yes	
Surgical treatment: resection of primary	ref19	1=no, 2=yes	
Surgical treatment: lymphatic mapping	ref20	1=no, 2=yes	
Surgical treatment: sentinel lymph node biopsy	ref21	1=no, 2=yes	
Surgical treatment: resection of local skin recurrence	ref22	1=no, 2=yes	
Surgical treatment: resection of regional recurrence	ref23	1=no, 2=yes	
Surgical treatment: sentinel lymph node dissection	ref24	1=no, 2=yes	
Surgical treatment: regional lymph node dissection	ref25	1=no, 2=yes	
Surgical treatment: resection of non-visceral distant recurrence	ref27	1=no, 2=yes	

Surgical treatment: resection of visceral distant recurrence	ref28	1=no, 2=yes	
Any other current or prior malignancy	ref04	1=no, 2=yes	
History of disease: cardiovascular/pulmonary	nm26	1=no, 2=yes	
History of disease: immunologic	nm27	1=no, 2=yes	
History of disease: neurologic/psychiatric	nm28	1=no, 2=yes	
History of disease: cancer other than melanoma	nm29	1=no, 2=yes	
History of disease: renal	nm30	1=no, 2=yes	
History of disease: hepatic	nm31	1=no, 2=yes	
History of disease: gastrointestinal	nm32	1=no, 2=yes	
History of disease: endocrinologic	nm33	1=no, 2=yes	
History of disease: genitourinary	nm34	1=no, 2=yes	
History of disease: dermatologic(not melanoma)	nm35	1=no, 2=yes	
History of disease: musculoskeletal	nm36	1=no, 2=yes	
Received protocol therapy	treated	0=no, 1=yes	
Total number of cycles completed	maxcycle	Continuous variable	777 of the 782 treated patients had treatment data
Reason for discontinuing protocol therapy	offtrt	String variable	Only patients who started protocol therapy answered the question.
Cause of death	cod	-1=cause was unknown 1=protocol treatment 2=melanoma 3=other cause	Only patients who died answered the question.
Site of second primary cancer	jn041-jn0411	See below for coding details*	A total of 73 patients developed second primary cancer during the study period, 55 of them had one second primary cancer and 18 patients had multiple new cancers. Information about second primary cancer was stored in the 11 variables

			named jn041-jn0411. Only patients who developed second primary cancer answered these questions.
--	--	--	---

\*Coding for site of second primary cancer (jn041-jn0411)

```

value site
101 = "Breast"
202 = "Colon"
203 = "Rectum"
204 = "Gastric"
205 = "pancreas"
207 = "Esophagus"
304 = "Brain Tumor"
405 = "Non-Hodgkins Lymphoma"
414 = "Acute Lymphocytic Leukemia - ALL"
502 = "Small Cell Lung"
503 = "Non-Small Cell Lung"
600 = "Melanoma"
601 = "Melanoma"
602 = "Basal Cell Carcinoma"
603 = "Skin cancer not melanoma"
801 = "Ovarian"
803 = "Renal Cell"
804 = "Bladder, Urinary Tract"
806 = "Prostate"
999 = "Multiple Sites"

```